# NeuroSense Therapeutics Ltd. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/NeuroSense Therapeutics Ltd.). ## Overview NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for neurodegenerative diseases. Its lead program, PrimeC, is a proprietary oral fixed-dose combination therapy designed to address multiple disease pathways implicated in ALS, and the company is based in Israel with U.S. capital market access. ## Products & services • PrimeC multi-pathway oral therapy for ALS • Clinical development of neurodegenerative disease treatments • Biomarker-driven translational research programs • Drug development support for regulatory submissions - **Lead therapeutic candidate** (80%) — PrimeC and related clinical-stage drug development for ALS and other neurodegenerative diseases. - **Research and preclinical programs** (20%) — Discovery and biomarker-based pipeline work supporting future indications and assets. - PrimeC multi-pathway oral therapy for ALS - Clinical development of neurodegenerative disease treatments - Biomarker-driven translational research programs - Drug development support for regulatory submissions ## Customers NeuroSense does not sell to a broad commercial customer base; its key stakeholders are patients, physicians, regulators, and clinical trial participants involved in the development and eventual use of its therapies. In practice, demand is driven by unmet medical need in ALS and related neurodegenerative diseases, while value creation depends on clinical data, regulatory milestones, and future commercialization partners or healthcare systems. - **ALS patients** (primary) — Patients with ALS are the core end beneficiaries of PrimeC and the main disease population the company is trying to address. - **Neurology specialists** (primary) — Neurologists and ALS clinics evaluate the clinical data and may prescribe the therapy if approved. - **Regulators** (primary) — Health Canada, the FDA, and other agencies review the evidence package for safety, efficacy, and manufacturing. - **Clinical trial participants** (primary) — Patients enrolled in studies generate the efficacy, biomarker, and safety data needed for development. - **Potential partners** (secondary) — Pharma or biotech partners may support development, commercialization, or geographic expansion. - ALS patients who may benefit from disease-modifying therapy - Neurologists and specialists who evaluate treatment options - Regulators reviewing clinical and safety evidence - Clinical trial participants enrolled in development studies - Potential commercialization or licensing partners ## Geography NeuroSense is headquartered in Israel, with principal executive offices in Herzliya, and it accesses U.S. capital markets through Nasdaq. Its development work is international in nature because clinical trials, regulatory submissions, and future commercialization for a specialty therapy can span multiple markets, including North America and other regulated geographies. - Headquartered in Herzliya, Israel - Uses U.S. public markets through Nasdaq listing - Clinical and regulatory activity spans North America - Future commercialization would depend on approved launch markets - Cross-border structure affects trial execution and financing ## Strategy The company’s strategy is to advance PrimeC through late-stage development and regulatory review as a potential treatment for ALS, while using biomarker and multi-pathway science to differentiate its approach. It is also expanding the development narrative beyond a single mechanism by positioning the program around multiple neurodegenerative pathways and by progressing regulatory engagement in Canada. - **Advance PrimeC regulatory submission** (short-term) — Regulatory filing is the key gateway from clinical development to potential commercialization. - **Strengthen clinical evidence base** (medium-term) — Late-stage biotech value depends on reproducible efficacy, safety, and biomarker results. - **Preserve financing flexibility** (short-term) — Development-stage biotechs require ongoing capital to fund trials, regulatory work, and operations. - Advance PrimeC through late-stage regulatory pathways - Use multi-pathway biomarker science to support differentiation - Build evidence in ALS and potentially adjacent neurodegenerative diseases - Pursue regulatory alignment with Health Canada and other agencies - Maintain access to external capital for development funding ## Risks NeuroSense faces the typical risks of a clinical-stage biotech, where value depends on trial outcomes, regulatory approvals, and access to financing before any product revenue exists. The company’s very small cash balance, dependence on a single lead asset, and exposure to complex neurodegenerative disease biology make execution and funding risk especially important. - **Clinical development risk** [critical] — PrimeC must demonstrate safety and efficacy in a very difficult disease area before it can become a commercial product. - **Regulatory approval risk** [high] — The company depends on health authority review and acceptance of its submission package and clinical data. - **Financing and liquidity risk** [critical] — Clinical-stage operations require external capital and the company reported very limited cash at year-end. - **Single-product concentration** [high] — The business currently relies heavily on one lead program, so setbacks would have outsized impact. - Clinical trial failure could materially impair asset value - Regulatory delays or rejection would push out commercialization - Single-asset dependence increases concentration risk - Financing risk is high due to limited cash and ongoing burn - Biology of ALS and related diseases remains difficult to treat ## Accounting As a clinical-stage biotech, NeuroSense’s reported results are shaped less by revenue accounting and more by research, development, and financing-related estimates. Investors should watch cash usage, lease accounting, and the measurement of liabilities and accrued expenses, since small changes in assumptions can materially affect the balance sheet and near-term liquidity picture. - **Research and development expense recognition** — Affects operating loss and comparability across quarters - **Lease accounting** — Affects balance sheet and operating expense presentation - **Accrued liabilities and trade payables** — Affects working capital and liquidity analysis - **Equity financing accounting** — Affects dilution and capital structure - No product revenue means expenses and funding dominate reported results - R&D and clinical trial costs are expensed as incurred - Lease accounting affects right-of-use assets and lease liabilities - Accrued liabilities and payables reflect unpaid development obligations - Fair value or equity issuance accounting may affect financing records --- *Last updated: 2026-09-28T12:13:25.034782+00:00*